Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.0
(0.0%)
USD 4.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.48 Billion USD | -10.01% |
| 2022 | 257.36 Million USD | 25.02% |
| 2021 | 205.85 Million USD | 65.33% |
| 2020 | 124.51 Million USD | 20.32% |
| 2019 | 103.48 Million USD | -82.63% |
| 2018 | 595.85 Million CNY | 42.95% |
| 2017 | 416.82 Million CNY | 109.58% |
| 2016 | 198.88 Million CNY | -6.91% |
| 2015 | 213.65 Million CNY | 26.08% |
| 2014 | 169.46 Million CNY | 66.04% |
| 2013 | 102.05 Million CNY | 41.84% |
| 2012 | 71.95 Million CNY | 30.67% |
| 2011 | 55.06 Million CNY | 59.48% |
| 2010 | 34.52 Million CNY | 320.52% |
| 2009 | 8.21 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 397.92 Million CNY | 8.96% |
| 2024 Q1 | 362.19 Million CNY | 6.17% |
| 2024 Q2 | 365.19 Million CNY | 16.08% |
| 2023 Q2 | 967.7 Million CNY | 1524.44% |
| 2023 FY | 231.61 Million USD | -10.01% |
| 2023 Q1 | 59.57 Million USD | 12.68% |
| 2023 Q4 | 175.21 Million CNY | -75.43% |
| 2023 Q3 | 713.12 Million CNY | -26.31% |
| 2022 Q3 | 70.6 Million USD | -91.46% |
| 2022 Q4 | 52.86 Million USD | -25.12% |
| 2022 Q2 | 826.53 Million CNY | 89.49% |
| 2022 Q1 | 436.18 Million CNY | 3.84% |
| 2022 FY | 257.36 Million USD | 25.02% |
| 2021 Q2 | 51.15 Million CNY | 50.06% |
| 2021 FY | 205.85 Million USD | 65.33% |
| 2021 Q3 | 363.7 Million CNY | 610.98% |
| 2021 Q4 | 420.06 Million CNY | 15.5% |
| 2021 Q1 | 34.09 Million CNY | -94.94% |
| 2020 Q2 | 839.87 Million CNY | 193.21% |
| 2020 Q3 | 422.25 Million CNY | -49.72% |
| 2020 Q4 | 673.73 Million CNY | 59.56% |
| 2020 FY | 124.51 Million USD | 20.32% |
| 2020 Q1 | 286.44 Million CNY | -32.54% |
| 2019 Q3 | 227.31 Million CNY | -8.67% |
| 2019 Q4 | 424.63 Million CNY | 86.8% |
| 2019 FY | 103.48 Million USD | -82.63% |
| 2019 Q1 | 183.78 Million CNY | -8.19% |
| 2019 Q2 | 248.9 Million CNY | 35.44% |
| 2018 Q1 | 115.39 Million CNY | -2.94% |
| 2018 FY | 595.85 Million CNY | 42.95% |
| 2018 Q3 | 120.41 Million CNY | -24.68% |
| 2018 Q4 | 200.17 Million CNY | 66.24% |
| 2018 Q2 | 159.87 Million CNY | 38.55% |
| 2017 Q3 | 113.12 Million CNY | -1.24% |
| 2017 FY | 416.82 Million CNY | 109.58% |
| 2017 Q4 | 118.88 Million CNY | 5.08% |
| 2017 Q2 | 114.54 Million CNY | 63.01% |
| 2017 Q1 | 70.26 Million CNY | 22.09% |
| 2016 Q1 | 51.76 Million CNY | -7.48% |
| 2016 Q2 | 51.65 Million CNY | -0.21% |
| 2016 FY | 198.88 Million CNY | -6.91% |
| 2016 Q4 | 57.55 Million CNY | 55.69% |
| 2016 Q3 | 36.96 Million CNY | -28.43% |
| 2015 Q2 | 58.79 Million CNY | 23.46% |
| 2015 Q3 | 51.28 Million CNY | -12.78% |
| 2015 Q4 | 55.95 Million CNY | 9.1% |
| 2015 Q1 | 47.62 Million CNY | -9.14% |
| 2015 FY | 213.65 Million CNY | 26.08% |
| 2014 Q2 | 37.33 Million CNY | 12.37% |
| 2014 Q1 | 33.22 Million CNY | 42.93% |
| 2014 FY | 169.46 Million CNY | 66.04% |
| 2014 Q4 | 52.41 Million CNY | 12.75% |
| 2014 Q3 | 46.48 Million CNY | 24.51% |
| 2013 FY | 102.05 Million CNY | 41.84% |
| 2013 Q1 | 25.03 Million CNY | 18.39% |
| 2013 Q3 | 24.92 Million CNY | -13.62% |
| 2013 Q4 | 23.24 Million CNY | -6.73% |
| 2013 Q2 | 28.85 Million CNY | 15.23% |
| 2012 Q1 | 15.21 Million CNY | 12.55% |
| 2012 Q3 | 16.94 Million CNY | -9.16% |
| 2012 Q4 | 21.14 Million CNY | 24.83% |
| 2012 FY | 71.95 Million CNY | 30.67% |
| 2012 Q2 | 18.65 Million CNY | 22.6% |
| 2011 Q3 | 12.48 Million CNY | 0.0% |
| 2011 Q4 | 13.51 Million CNY | 8.25% |
| 2011 FY | 55.06 Million CNY | 59.48% |
| 2010 FY | 34.52 Million CNY | 320.52% |
| 2009 FY | 8.21 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 200336.76% |
| Arrayit Corporation | -3.62 Million USD | 68752.262% |
| Atlantic International Corp. | -5.73 Million USD | 43483.108% |
| Biocept, Inc. | -31.98 Million USD | 7875.82% |
| Bioqual, Inc. | -19.63 Thousand USD | 12664019.732% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 322183.316% |
| DermTech, Inc. | -103.73 Million USD | 2497.305% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 12039.457% |
| iMD Companies, Inc. | -175.44 Thousand USD | 1417596.299% |
| IDenta Corp. | -1499.00 USD | 165906741.561% |
| Interpace Biosciences, Inc. | 2.8 Million USD | -88592.602% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -6427763.936% |
| InVitro International | -25.33 Thousand USD | 9814775.232% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 35019.132% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 4279664.56% |
| Medical Imaging Corp. | -819.48 Thousand USD | 303577.883% |
| NovelStem International Corp. | -3.52 Million USD | 70635.517% |
| Optigenex Inc. | 1.39 Million USD | -178709.173% |
| PharmChem, Inc. | 973.14 Thousand USD | -255456.515% |
| Proteome Sciences plc | -1.62 Million USD | 153520.145% |
| Response Genetics, Inc | -21.37 Million USD | 11733.721% |
| Rennova Health, Inc. | -1.4 Million USD | 176537.075% |
| RushNet, Inc. | -684.7 Thousand USD | 363313.436% |
| ScreenPro Security Inc. | -2.59 Million USD | 96030.94% |
| Stella Diagnostics Inc. | -11.42 Million USD | 21863.818% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 32202.973% |
| Todos Medical Ltd. | -9.74 Million USD | 25612.316% |